Procalcitonin (PCT) is a 116 amino acid residue protein with a molecular weight of approximately 13kDa. Procalcitonin is a peptide hormone mainly produced by the C cells of the thyroid and certain endocrine cells of the lung. Under normal expression conditions, procalcitonin is immediately cleaved into three specific fragments, an N terminal residue, calcitonin and katacalcin. It can be expressed in E. coli.Procalcitonin Antibody refers to the specific protein which can qualitatively and quantitatively detect the PCT level. PCT level is a parameter for the diagnosis and monitoring of bacterial inflammatory diseases
Scope of the Report:Sepsis is a life-threatening organ dysfunction caused by an excessive host immune response to a serious infection. According to the Centers for Disease Control and Prevention (CDC), 1.6 million Americans suffered from sepsis in 2011, of which about 260,000 did not survive. PCT can play a critical role in addressing this clinical challenge and has become a key component of successful sepsis protocols across the U.S. and Europe. PCT levels increase precipitously in patients with severe bacterial infection. PCT is therefore an extremely important biomarker enabling specific differentiation between a severe bacterial infection and other causes of inflammatory reactions.
The technical barriers of procalcitonin antibody are high and the procalcitonin antibody production concentrated large companies including Thermo Fisher, Roche Diagnostics, bioMerieux, HyTest, etc. The sales revenue of top five manufacturers accounted for 37.9% in 2016. Thermo Fisher is the largest manufacturer in the world, which sales reached 2.48g in China.
The manufacture region is concentrated in South China, East China and Southwest China, of which East China is the largest region with the share 24.28% in 2016. The sales shares of Southwest China and South China were 15.59% and 14.79%.
There are companies adding new capacities and aims at the cost and quality leadership which shall improve profitability. As the same time, companies are focusing on technological innovation, equipment upgrades, and process improvements, to reduce costs and improve quality. The competition in procalcitonin antibody market will become more intense.
The worldwide market for Procalcitonin Antibody is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2026, from xx million US$ in 2020, according to a new Our study.
This report focuses on the Procalcitonin Antibody in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers Thermo Fisher
Roche Diagnostics
bioMerieux
HyTest
Wondfo
Ningbo Medicalsystem Biotechnology
Snibe
Vazyme Biotech
Getein Biotech
Hotgen Biotech
Lumigenex
Shanghai Medicine'nest Pharmaceutical
Kitgen
Beijing KeyGen
Fantibody
Market Segment by Regions, regional analysis covers North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers Polyclonal Procalcitonin Antibody
Monoclonal Procalcitonin Antibody
Market Segment by Applications, can be divided into Hospital
Medical research institutions
Others
The content of the study subjects, includes a total of 15 chapters:Chapter 1, to describe Procalcitonin Antibody product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Procalcitonin Antibody, with price, sales, revenue and global market share of Procalcitonin Antibody in 2018 and 2019.
Chapter 3, the Procalcitonin Antibody competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Procalcitonin Antibody breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Procalcitonin Antibody market forecast, by regions, type and application, with sales and revenue, from 2020 to 2026.
Chapter 13, 14 and 15, to describe Procalcitonin Antibody sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.